Redefining disease

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 10, Issue 6, 2010, Pages 584-594

  Bell, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; IMATINIB; PLX 4032; TRASTUZUMAB;

BREAST CANCER; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CROHN DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENERAL ASPECTS OF DISEASE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTORY OF MEDICINE; HUMAN; HUMAN GENOME; INFECTION; INFLAMMATION; LUNG CANCER; MELANOMA; METASTASIS; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NONHUMAN;

EID: 78650331530     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.10-6-584     Document Type: Conference Paper

References (80)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
2. Russell PS,Winn HJ (eds). Histocompatibility testing.Washington DC: National Academy of Sciences National Research Council, Publication 1229, 1965.
3. Jeffreys AJ,Wilson V, Thein SL. Hypervariable 'minisatellite' regions in human DNA. Nature 1985;314:67-73.
4. Beckman JS,Weber JL. Survey of human and rat microsatellites. Genomics 1992;12:627-31.
5. Macilwain C.World leaders heap praise on human genome landmark. Nature 2000;405:983-4.
6. Sachidanandam R,Weissman D, Schmidt SC et al. International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-33.
7. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 2003;33(Suppl):228-37. (Pubitemid 36278833)
8. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437(7063):1299-320.
9. International HapMap Consortium, Frazer KA, Ballinger DG et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-61.
10. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9.
11. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
12. Todd JA. Etiology of type 1 diabetes. Immunity 2010;32:457-67.
13. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40(8):955-62.
14. Imielinski M, Baldassano RN, Griffiths A et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009;41:1335-40.
15. UK IBD Genetics Consortium, Barrett JC, Lee JC et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009;41:1330-4.
16. Kanneganti TD, Lamkanfi M, Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007;27:549-59. (Pubitemid 47615512)
17. Rodrigue-Gervais IG, Saleh M. Genetics of inflammasome-associated disorders: a lesson in the guiding principals of inflammasome function. Eur J Immunol 2010;40:643-8.
18. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458-66.
19. Franchi L,Warner N, Viani K, Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009;227:106-28.
20. Cooney R, Baker J, Brain O et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010;16:90-7.
21. Todd JA. D'oh! genes and environment cause Crohn's disease. Cell 2010;141:1114-16.
22. Travassos LH, Carneiro LA, Ramjeet M et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:55-62.
23. Cadwell K, Patel KK,Maloney NS et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010;141:1135-45.
24. Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 2009;361:2666-8.
25. Zhang FR, Huang W, Chen SM et al. Genome wide association study of leprosy. N Engl J Med 2009;361:2609-18.
26. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
27. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-45. (Pubitemid 46245771)
28. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50.
29. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
30. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123-7.
31. Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev 2010;233:162-80.
32. Davidson SI,Wu X, Liu Yet al. Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum 2009;60:3263-8.
33. Osler W. The principles and practice of medicine. New York: D Appleton and Company, 1892.
34. McCarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes 2008;57:2889-98.
35. Shimomura K, Flanagan SE, Zadek B et al. Adjacent mutations in the gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. EMBO Mol Med 2009;1:166-77.
36. Zeggini E, Scott LJ, Saxena R et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40:638-45. (Pubitemid 351601209)
37. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-16.
38. Voight BF, Scott LJ, Steinthorsdottir V et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-89.
39. Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 2008;51:1100-10.
40. Park JH,Wacholder S, Gail MH et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010;42:570-5.
41. Gibson G. Hints of hidden heritability in GWAS. Nat Genet 2010;42:558-60.
42. Pinto D, Pagnamenta AT, Klei L et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010;466:368-72.
43. Cohen JC, Kiss RS, Pertsemlidis A et al.Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004;305:869-72.
44. Hegele RA, Cao H, Harris SB et al. The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 1999;84:1077-82.
45. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010;141:210-7.
46. Dror AA, Avraham KB. Hearing loss: mechanisms revealed by genetics and cell biology. Annu Rev Genet 2009;43:411-37.
47. Skuse DH. Rethinking the nature of genetic vulnerability to autistic spectrum disorders. Trends Genet 2007;23:387-95.
48. Cook EH Jr, Scherer SW. Copy-number variations associated with neuropsychiatric conditions. Nature 2008;455:919-23.
49. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008;455: 237-41.
50. Sebat J, Levy DL, McCarthy SE. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet 2009;25:528-35.
51. Walsh T,McClellan JM, McCarthy SE et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008;320:539-43.
52. Stoddart D,Maglia G,Mikhailova E, Heron AJ, Bayley H.Multiple base-recognition sites in a biological nanopore: two heads are better than one. Angew Chem Int Ed Engl 2010;49:556-9.
53. Stoddart D, Heron AJ,Mikhailova E,Maglia G, Bayley H. Singlenucleotide discrimination in immobilized DNA oligonucleotides with a biological nanopore. Proc Natl Acad Sci USA 2009;106:7702-7.
54. Banerjee S, Kaye SB, Ashworth A; Medscape.Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010;7:508-19.
55. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
56. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
57. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
58. Travis RC, Reeves GK, Green J et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 2010;375:2143-51.
59. Vogelstein B. The sequence of all 185,000 coding exons in each of 100 human tumors:What has it taught us? Webcast of American Association for Cancer Research 101st Annual Meeting 2010. app2.capitalreach.com/esp1204/servlet/tc?cn= aacr&c=10165&s=20435&e=12624&&m=1&br=80&audio=false
60. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
61. Kloosterhof NK, Bralten LB, Dubbink HJ et al. Isocitrate dehydrogenase- 1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 2010 Jul 6 [epub ahead of print].
62. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
63. Frezza C, Tennant DA, Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 2010;17:7-9.
64. Dang L,White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
65. Smeitink J.Metabolism, gliomas, and IDH1. N Engl J Med 2010;362:1144-5.
66. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
67. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357(3):258-65.
68. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 20075;357:39-51.
69. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
70. Rosell R,Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
71. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
72. Mok TS,Wu YL, Thongprasert S et al. Gefitinib or carboplatin-placlitaxel in pulmonary adenocarcinoma. N Eng J Med 2009;361:947-57.
73. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
74. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
75. Joseph EW, Pratilas CA, Poulikakos PI et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010;107:14903-8.
76. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
77. Palmer LJ. UK Biobank: bank on it. Lancet 2007;369:1980-2.
78. Tan GD, Neville MJ, Liverani E et al. The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia 2006;49:158-68.
79. Dendrou CA, Plagnol V, Fung E et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009;41:1011-5.
80. Gregersen JW, Kranc KR, Ke X et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006;443:574-7.